secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2022-12-14T23:59:59+00:00
Accession:  0001213900-22-079827
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea settles with Camac Group; to repurchase 3.2M shares at $1.0003, standstill 3 years
--------------------------------------------------------------------------------

- Will buy back 3,205,282 shares (11% of outstanding) at $1.0003 per share (trailing 5-day VWAP).
- Reimburses Camac Group expenses up to $689,491; both parties dismiss Delaware litigation with prejudice.
- Camac Group enters 3-year standstill, agrees not to engage in proxy contests or change-of-control actions.
- Special meeting Dec 9, 2022: all proposals to remove five directors and repeal bylaw changes were denied by shareholders.
- Mutual release of claims related to Camac investment, special meeting, and prior acquisitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390022079827/0001213900-22-079827-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390022079827/ea170172-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-079827

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer